Navigation Links
Experiments reveal unexpected activity of fuel cell catalysts
Date:12/13/2007

been reported as very efficient catalysts for the WGS reaction, said Brookhaven chemist Jan Hrbek. This was a surprising finding because neither bulk gold nor bulk ceria and titania are active as catalysts.

To determine how these nanocatalysts work, the research team developed so-called inverse model catalysts. The WGS catalysts usually consist of gold nanoparticles dispersed on a ceria or titania surface a small amount of the expensive metal placed on the inexpensive oxide. But to get a better look at the surface interactions, the researchers placed ceria or titania nanoparticles on a pure gold surface.

For the first time, we established that although pure gold is inert for the WGS reaction, if you put a small amount of ceria or titanium on it, it becomes extremely active, Rodriguez said. So although these inverse catalysts are just models, they have catalytic activity comparable to, and sometimes better than, the real deal.

Using a technique called x-ray photoelectron spectroscopy at Brookhavens National Synchrotron Light Source, as well as scanning tunneling microscopy and calculations, the researchers discovered that the catalysts oxides are the reason for their high activity.

The oxides have unique properties on the nanoscale and are able to break apart water molecules, which is the most difficult part of the WGS reaction, Hrbek said. Added Brookhaven physicist Ping Liu: After you dissociate the water, the reaction continues on to eliminate CO. But if you dont have nanosized oxide particles, none of this will work.

The researchers plan to continue their study of these catalysts at the NSLS and CFN in order to further explore the reaction mechanism and optimize its performance.


'/>"/>

Contact: Karen McNulty Walsh
kmcnulty@bnl.gov
631-344-8350
DOE/Brookhaven National Laboratory
Source:Eurekalert

Page: 1 2

Related biology technology :

1. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
2. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
3. New Data Reveal Ethnicity May Play Role in Weight Loss Decisions
4. New paper reveals nanoscale details of photolithography process
5. Stem Cell Agency Finally Reveals Institutions Involved in Conflict Problem
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
8. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
9. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
10. Using catalysts to stamp nanopatterns without ink
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 2Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 3Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 4Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 5Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 6Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 7Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 2Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 3Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 4Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R) 2Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R) 3